Marker Therapeutics, Inc. (MRKR)

4.2950 +0.1950 (+4.76%) As of 11:35AM EDT. Market open.

Marker Therapeutics, Inc.

9350 Kirby Drive
Suite 300
Houston, TX 77054
United States
713 400 6400
https://markertherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 8

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Juan F. Vera M.D.	Co-Founder, CEO, President, Treasurer, Secretary & Director	399.25k	N/A	1980
Ms. Elizabeth Donnelly	Director of Administration	N/A	N/A	N/A
Dr. Robert Z. Florkiewicz Sr.	Senior Director of Molecular Biology & Virology	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Corporate governance

Marker Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.